Literature DB >> 22926232

Severe propylene glycol toxicity secondary to use of anti-epileptics.

Unnikrishnan Pillai1, Jatinder C Hothi, Zeenat Y Bhat.   

Abstract

Propylene glycol toxicity presenting as high anion gap metabolic acidosis and osmolar gap has been extensively reported in literature, and most of them are secondary to intravenous lorazepam infusion. However, propylene glycol is used as a solvent in a number of medications that are frequently utilized in critical care setting, and hence one should be aware that the toxicity is possible from a variety of medication. Phenobarbital and phenytoin are one of those, and we hereby report a novel case of propylene glycol toxicity secondary to phenobarbital and phenytoin infusion in a patient with refractory status epilepticus. Furthermore, our patient had end-stage renal disease, which we think could have been an important precipitating factor for the toxicity. Because most of the symptoms from propylene glycol toxicity can mimic sepsis-which is very common in critical care unit patients-this life threatening scenario could be easily missed. Regular monitoring of osmolar gap is an easily available intervention in the at risk patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 22926232     DOI: 10.1097/MJT.0b013e31824c407d

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

Review 1.  Systemic Complications Following Status Epilepticus.

Authors:  Maximiliano A Hawkes; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-07       Impact factor: 5.081

2.  Management of super-refractory status epilepticus with isoflurane and hypothermia.

Authors:  Agzam Zhumadilov; Charles P Gilman; Dmitriy Viderman
Journal:  Front Neurol       Date:  2015-01-28       Impact factor: 4.003

3.  Potentiation of Sodium Metabisulfite Toxicity by Propylene Glycol in Both in Vitro and in Vivo Systems.

Authors:  Jean Yoo; Yeon-Mi Lim; Haewon Kim; Eun-Ji Kim; Doo-Hee Lee; Byeongwoo Lee; Pilje Kim; Seung Do Yu; Hyun-Mi Kim; Byung-Il Yoon; Ilseob Shim
Journal:  Front Pharmacol       Date:  2018-02-28       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.